CN113166071B - 尼拉帕利盐 - Google Patents

尼拉帕利盐 Download PDF

Info

Publication number
CN113166071B
CN113166071B CN201980078366.1A CN201980078366A CN113166071B CN 113166071 B CN113166071 B CN 113166071B CN 201980078366 A CN201980078366 A CN 201980078366A CN 113166071 B CN113166071 B CN 113166071B
Authority
CN
China
Prior art keywords
crystalline form
indazole
piperidin
carboxamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980078366.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113166071A (zh
Inventor
A.J.斯图尔特
Y.王
G.吴
J.尹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texano Ltd
Original Assignee
Texano Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texano Ltd filed Critical Texano Ltd
Priority to CN202411070879.7A priority Critical patent/CN118994103A/zh
Publication of CN113166071A publication Critical patent/CN113166071A/zh
Application granted granted Critical
Publication of CN113166071B publication Critical patent/CN113166071B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980078366.1A 2018-10-03 2019-10-03 尼拉帕利盐 Active CN113166071B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411070879.7A CN118994103A (zh) 2018-10-03 2019-10-03 尼拉帕利盐

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862740872P 2018-10-03 2018-10-03
US62/740,872 2018-10-03
PCT/US2019/054534 WO2020072797A1 (en) 2018-10-03 2019-10-03 Niraparib salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411070879.7A Division CN118994103A (zh) 2018-10-03 2019-10-03 尼拉帕利盐

Publications (2)

Publication Number Publication Date
CN113166071A CN113166071A (zh) 2021-07-23
CN113166071B true CN113166071B (zh) 2025-03-21

Family

ID=68345029

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980078366.1A Active CN113166071B (zh) 2018-10-03 2019-10-03 尼拉帕利盐
CN202411070879.7A Pending CN118994103A (zh) 2018-10-03 2019-10-03 尼拉帕利盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411070879.7A Pending CN118994103A (zh) 2018-10-03 2019-10-03 尼拉帕利盐

Country Status (7)

Country Link
EP (1) EP3860981B1 (https=)
JP (1) JP7472115B2 (https=)
KR (1) KR20210071022A (https=)
CN (2) CN113166071B (https=)
ES (1) ES2967517T3 (https=)
TW (2) TW202513550A (https=)
WO (1) WO2020072797A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI905184B (zh) 2020-05-08 2025-11-21 比利時商健生藥品公司 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌
JP2024525881A (ja) 2021-07-19 2024-07-12 ヤンセン ファーマシューティカ エヌ．ベー． ニラパリブ（ｎｉｒａｐａｒｉｂ）による転移性去勢抵抗性前立腺癌の治療
CN121311226A (zh) 2023-05-17 2026-01-09 特沙诺有限公司 聚adp核糖聚合酶(parp)抑制剂在治疗癌症中的新用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108160A1 (zh) * 2016-12-16 2018-06-21 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
WO2018122168A1 (en) * 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (https=) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
KR101653548B1 (ko) * 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
MX2019005116A (es) 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
JP2019533458A (ja) 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
WO2018129553A1 (en) 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-tim-3 antibodies
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108160A1 (zh) * 2016-12-16 2018-06-21 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
WO2018122168A1 (en) * 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors

Also Published As

Publication number Publication date
CN118994103A (zh) 2024-11-22
TW202028181A (zh) 2020-08-01
KR20210071022A (ko) 2021-06-15
TW202513550A (zh) 2025-04-01
EP3860981A1 (en) 2021-08-11
EP3860981B1 (en) 2023-11-29
WO2020072797A1 (en) 2020-04-09
ES2967517T3 (es) 2024-04-30
JP7472115B2 (ja) 2024-04-22
JP2022504236A (ja) 2022-01-13
CN113166071A (zh) 2021-07-23
TWI853841B (zh) 2024-09-01

Similar Documents

Publication Publication Date Title
JP7502368B2 (ja) ６－（２－ヒドロキシ－２－メチルプロポキシ）－４－（６－（６－（（６－メトキシピリジン－３－イル）メチル）－３，６－ジアザビシクロ［３．１．１］ヘプタン－３－イル）ピリジン－３－イル）ピラゾロ［１，５－ａ］ピリジン－３－カルボニトリルを含む製剤
RU2754856C2 (ru) Кристаллические формы соединения триазолопиримидина
TWI633103B (zh) 選擇性ｃｄｋ４／６抑制劑之固態形式
CN102245023B (zh) 取代的二氧代哌啶基邻苯二甲酰亚胺衍生物
CA3210612C (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR102498693B1 (ko) 정제 조성물
CN113166071B (zh) 尼拉帕利盐
US12297184B2 (en) Niraparib salts
CN119013018A (zh) 包含泛素特异性加工蛋白酶1(usp1)抑制剂和化疗剂的治疗组合
JP2017529356A (ja) チロシンキナーゼ阻害剤及びその塩の結晶形態
HK40120176A (zh) 尼拉帕利盐
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
JP2026505728A (ja) ６－（３－（（５－クロロ－２－メトキシピリジン）－３－スルホンアミド）－２，６－ジフルオロフェニル）－ｎ－メチルイミダゾ［１，５－ａ］ピラジン－１－カルボキサミドの結晶形態及びその使用方法
HK40048853B (en) Niraparib salts
HK40048853A (en) Niraparib salts
TW202543622A (zh) Ｃｓｆ－１ｒ抑制劑之調配物
TW202542127A (zh) 激酶抑制劑之固態形式
JP2024502130A (ja) チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤の形態及び製剤
TW202408509A (zh) 雜芳基衍生物的藥物組合物及其在醫藥上的應用
KR20250040692A (ko) Akr1c3 의존성 kars 억제제의 결정질 형태
TWI765848B (zh) 喹諾酮類似物及其鹽的結晶形式
TW201136935A (en) Salts of an indazolylpyrrolotriazine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Delaware, USA

Patentee after: Texano Ltd.

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: Texano Ltd.

Country or region before: U.S.A.